Strategic partnership Potential for expanded collaboration with Sygnature Discovery across protein expression, structure-based drug design, and in vivo pharmacology since they offer integrated protein services and recently expanded their platform with ExpiCHO-S and new leadership in In Vivo Pharmacology.

Integrated toolkit Opportunity to package and upsell by aligning with Sygnature’s computational and medicinal chemistry toolkit (SygDesign, BullFrog AI, Iktos) for end-to-end drug discovery, leveraging their recent integration deals.

Clinical programs Exposure to early-stage and preclinical programs via their collaboration with STORM Therapeutics on DHX9 inhibitors suggests a demand for specialized protein expression and structure services to accelerate preclinical development.

Expansion and branding Leverage their brand relaunch and new website to create co-marketing opportunities, joint webinars, and thought leadership to attract clients seeking modern, integrated CRO partnerships.

Cost and headcount dynamics Be prepared to address pricing flexibility and capacity planning given recent headcount reductions; position as a scalable partner with adaptable resourcing and offshore/CAN capabilities if applicable.